Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Shows Efficacy, Tolerability in CLL
May 1st 2022The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.
Aliènne Salleroli on Establishing Equity, Diversity, and Inclusion Throughout Oncology Practice
April 29th 2022The framework for establishing equity, diversity, and inclusion throughout oncology nursing already exists within the standard for health and safety, explains Aliènne Salleroli, MS, BSN, RN, OCN.
Nurses Can Build Strategies to Facilitate More Meaningful Discussions With Patients and Caregivers
April 28th 2022Oncology nurses are in less control of their communication environment compared with other health care providers; however, certain strategies can help them communicate effectively with their patients.
2022 ASCO Gastrointestinal Cancers Symposium Highlights
April 20th 2022Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.
Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer
April 18th 2022New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.